EGFR and non-small cell lung carcinoma: The identification of ALK rearrangements, found in approximately 5% of non-small-cell lung cancers (NSCLCs), and the success of tyrosine-kinase inhibitors (TKI) (crizotinib, ceritinib, alectinib and brigatinib), have provided a breakthrough similar to the discovery of EGFR mutations and treatment [2].